Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. more
Time Frame | LGND | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.94% | -3.39% | -3.47% |
1-Month Return | 2.45% | -3.25% | -0.29% |
3-Month Return | 10.35% | -11.61% | 4.5% |
6-Month Return | 42.05% | -5.89% | 6.91% |
1-Year Return | 65.33% | 2.65% | 23.79% |
3-Year Return | 19.7% | 0.56% | 28.43% |
5-Year Return | 70.11% | 34.63% | 83.64% |
10-Year Return | 251.81% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 120.28M | 186.42M | 277.13M | 196.25M | 131.31M | [{"date":"2019-12-31","value":43.4,"profit":true},{"date":"2020-12-31","value":67.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.81,"profit":true},{"date":"2023-12-31","value":47.38,"profit":true}] |
Cost of Revenue | 11.35M | 30.42M | 62.18M | 52.83M | 35.05M | [{"date":"2019-12-31","value":18.25,"profit":true},{"date":"2020-12-31","value":48.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.96,"profit":true},{"date":"2023-12-31","value":56.37,"profit":true}] |
Gross Profit | 108.94M | 156.00M | 214.96M | 143.42M | 96.27M | [{"date":"2019-12-31","value":50.68,"profit":true},{"date":"2020-12-31","value":72.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.72,"profit":true},{"date":"2023-12-31","value":44.78,"profit":true}] |
Gross Margin | 90.57% | 83.68% | 77.56% | 73.08% | 73.31% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.4,"profit":true},{"date":"2021-12-31","value":85.64,"profit":true},{"date":"2022-12-31","value":80.69,"profit":true},{"date":"2023-12-31","value":80.95,"profit":true}] |
Operating Expenses | 114.66M | 147.27M | 136.06M | 140.38M | 84.32M | [{"date":"2019-12-31","value":77.85,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":92.39,"profit":true},{"date":"2022-12-31","value":95.32,"profit":true},{"date":"2023-12-31","value":57.26,"profit":true}] |
Operating Income | (5.72M) | 8.55M | 78.89M | (25.50M) | 11.94M | [{"date":"2019-12-31","value":-7.25,"profit":false},{"date":"2020-12-31","value":10.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-32.33,"profit":false},{"date":"2023-12-31","value":15.14,"profit":true}] |
Total Non-Operating Income/Expense | 795.04M | (55.73M) | (50.39M) | 33.22M | 57.99M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.01,"profit":false},{"date":"2021-12-31","value":-6.34,"profit":false},{"date":"2022-12-31","value":4.18,"profit":true},{"date":"2023-12-31","value":7.29,"profit":true}] |
Pre-Tax Income | 796.64M | (10.54M) | 47.30M | 36.01M | 63.66M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1.32,"profit":false},{"date":"2021-12-31","value":5.94,"profit":true},{"date":"2022-12-31","value":4.52,"profit":true},{"date":"2023-12-31","value":7.99,"profit":true}] |
Income Taxes | 167.34M | (7.55M) | (10.29M) | 41.23M | 9.84M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-4.51,"profit":false},{"date":"2021-12-31","value":-6.15,"profit":false},{"date":"2022-12-31","value":24.64,"profit":true},{"date":"2023-12-31","value":5.88,"profit":true}] |
Income After Taxes | 629.30M | (2.98M) | 57.59M | (5.22M) | 53.82M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.47,"profit":false},{"date":"2021-12-31","value":9.15,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":8.55,"profit":true}] |
Income From Continuous Operations | 629.30M | (2.98M) | 57.59M | (5.22M) | 21.10M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.47,"profit":false},{"date":"2021-12-31","value":9.15,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":3.35,"profit":true}] |
Income From Discontinued Operations | (9.58M) | (9.58M) | (19.21M) | (28.14M) | - | [{"date":"2019-12-31","value":-958300000,"profit":false},{"date":"2020-12-31","value":-958300000,"profit":false},{"date":"2021-12-31","value":-1921500000,"profit":false},{"date":"2022-12-31","value":-2814200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 629.30M | (2.98M) | 57.14M | (5.22M) | 52.15M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.47,"profit":false},{"date":"2021-12-31","value":9.08,"profit":true},{"date":"2022-12-31","value":-0.83,"profit":false},{"date":"2023-12-31","value":8.29,"profit":true}] |
EPS (Diluted) | 3.04 | 4.55 | 6.42 | 4.28 | 6.10 | [{"date":"2019-12-31","value":47.35,"profit":true},{"date":"2020-12-31","value":70.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.67,"profit":true},{"date":"2023-12-31","value":95.02,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
LGND | |
---|---|
Cash Ratio | 8.87 |
Current Ratio | 12.49 |
Quick Ratio | 11.95 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LGND | |
---|---|
ROA (LTM) | 1.30% |
ROE (LTM) | 6.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LGND | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LGND | |
---|---|
Trailing PE | 45.95 |
Forward PE | 18.55 |
P/S (TTM) | 14.18 |
P/B | 2.57 |
Price/FCF | 97 |
EV/R | 12.78 |
EV/Ebitda | 20.35 |
PEG | 1.53 |
Ligand Pharmaceuticals Incorporated (LGND) share price today is $114.09
Yes, Indians can buy shares of Ligand Pharmaceuticals Incorporated (LGND) on Vested. To buy Ligand Pharmaceuticals Incorporated from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LGND stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ligand Pharmaceuticals Incorporated (LGND) via the Vested app. You can start investing in Ligand Pharmaceuticals Incorporated (LGND) with a minimum investment of $1.
You can invest in shares of Ligand Pharmaceuticals Incorporated (LGND) via Vested in three simple steps:
The 52-week high price of Ligand Pharmaceuticals Incorporated (LGND) is $129.9. The 52-week low price of Ligand Pharmaceuticals Incorporated (LGND) is $67.53.
The price-to-earnings (P/E) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 45.9478
The price-to-book (P/B) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 2.57
The dividend yield of Ligand Pharmaceuticals Incorporated (LGND) is 0.00%
The market capitalization of Ligand Pharmaceuticals Incorporated (LGND) is $2.16B
The stock symbol (or ticker) of Ligand Pharmaceuticals Incorporated is LGND